A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)

Authors:

Abstract
S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and homozygous for UGT1A1 *6 or *28 or compound heterozygous (*6/*28) were excluded. A dose‐escalation design was chosen for the phase I portion (level 1: irinotecan 80 mg/m2 days 1–8 and S‐1 80 mg/m2 days 1–14 every 3 weeks; level 2: irinotecan 100 mg/m2 and S‐1 80 mg/m2). Study objectives included determination of the recommended dose for phase II, response rate, progression‐free survival (PFS), and safety. Pharmacokinetics and CD34+ circulating endothelial cells (CECs) as pharmacodynamics were also analyzed. Thirty‐seven patients were included. One patient at each level developed dose‐limiting toxicities; therefore, level 2 was the recommended dose for phase II. Diarrhea was more common in patients possessing a *6 or *28 allele compared with wild‐type homozygous patients (46% and 25%). Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06). PFS was significantly longer in patients with a larger‐than‐median SN‐38 area under the curve (AUC) than in those with a smaller AUC (P = 0.039). There was an association between clinical benefit and reduction in baseline CD34+ CECs by S‐1 (P = 0.047). The combination of irinotecan and S‐1 is effective and warrants further investigation.
Funding Information
  • Grant-in-Aid for Scientific Research (JP24590656)
  • Advanced Clinical Research Organization

This publication has 19 references indexed in Scilit: